Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Mind Medicine (MindMed) Inc N.MMED.WR


Primary Symbol: MNMD Alternate Symbol(s):  N.MMED.WS | N.MMED.WA | N.MMED

Mind Medicine (MindMed) Inc. is a clinical-stage biopharmaceutical company, which is engaged in developing products to treat brain health disorders. It is developing a pipeline of product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways. This specifically includes pharmaceutically optimized product candidates derived from the psychedelic and empathogen drug classes, including MM-120 and MM-402, the Company's product candidates. MM120, is a proprietary, pharmaceutically optimized form of lysergide D-tartrate that it is developing for the treatment of generalized anxiety disorder (GAD). MM-120 is also being studied in a subperceptual repeat administration dosing regimen for the treatment of attention deficit hyperactivity disorder (ADHD). MM-402, also referred to as R(-)-MDMA, is the Company's form of the R-enantiomer of 3,4-methylenedioxymethampheta (MDMA), which the Company is developing for the treatment of autism spectrum disorder (ASD).


NDAQ:MNMD - Post by User

Comment by TeddyTenBagson Mar 25, 2021 8:46pm
206 Views
Post# 32883708

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Price action

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Price action"The fundamentals aren't important, but I want shares closer to fundamental value". Way to contradict yourself. 

There are no fundamentals for this stock - it's a purely speculative play as I've pointed out several times. Point I'm making of $500M vs. $1B is that there's nothing to support either valuation. Of course you want cheaper shares, but what supports buying at either of those valuations? Literally nothing other than speculation. 

There's no support at $2 and you can't justify it either because you got the number from a random number generator in excel. 

I want this stock to blow up as much as anybody long term with 51k shares at an avg of $0.98, but if you want to talk about adding value to the board, people should come with some facts to back up their "price targets", otherwise it's a bunch of amateurs throwing around terms they read on reddit after investing for a couple of months.

Gilly123 wrote: The fundamentals arent so important for this stock. This is a spec play. Now that some of the euphoria has worn off MMed seems to be trickling down in price. There is no support from where we are now until $2. So without a catalyst it could easily fall to those levels. Potentially it could be a nice bounce target for a pump. Why would I still be interested in a 500million valuation over a billion? What a dumb question. I want cheaper shares closer to fundamental value.


<< Previous
Bullboard Posts
Next >>